%0 Journal Article
%A Escamilla-Gomez, Virginia
%A Garcia-Gutierrez, Valentin
%A Lopez-Corral, Lucia
%A Garcia-Cadenas, Irene
%A Perez-Martinez, Ariadna
%A Marquez-Malaver, Francisco J
%A Caballero-Velazquez, Teresa
%A Gonzalez-Sierra, Pedro A
%A Viguria-Alegria, Maria C
%A Parra-Salinas, Ingrid M
%A Calderon-Cabrera, Cristina
%A Gonzalez-Vicent, Marta
%A Rodriguez-Torres, Nancy
%A Parody-Porras, Rocio
%A Ferra-Coll, Christelle
%A Orti, Guillermo
%A Valcarcel-Ferreiras, David
%A De-la-Camara-LLanza, Rafael
%A Moles, Paula
%A Velazquez-Kennedy, Kyra
%A João-Mende, Maria
%A Caballero-Barrigon, Dolores
%A Perez, Estefania
%A Martino-Bofarull, Rodrigo
%A Saavedra-Gerosa, Silvanna
%A Sierra, Jorge
%A Poch, Marc
%A Zudaire-Ripa, Maria T
%A Diaz-Perez, Miguel A
%A Molina-Angulo, Blanca
%A Sanchez-Ortega, Isabel
%A Sanz-Caballer, Jaime
%A Montoro-Gomez, Juan
%A Espigado-Tocino, Ildefonso
%A Perez-Simon, Jose A
%T Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study.
%D 2020
%U http://hdl.handle.net/10668/14653
%X Graft-versus-host disease is the main cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation. First-line treatment is based on the use of high doses of corticosteroids. Unfortunately, second-line treatment for both acute and chronic graft-versus-host disease, remains a challenge. Ruxolitinib has been shown as an effective and safe treatment option for these patients. Seventy-nine patients received ruxolitinib and were evaluated in this retrospective and multicenter study. Twenty-three patients received ruxolitinib for refractory acute graft-versus-host disease after a median of 3 (range 1-5) previous lines of therapy. Overall response rate was 69.5% (16/23) which was obtained after a median of 2 weeks of treatment, and 21.7% (5/23) reached complete remission. Fifty-six patients were evaluated for refractory chronic graft-versus-host disease. The median number of previous lines of therapy was 3 (range 1-10). Overall response rate was 57.1% (32/56) with 3.5% (2/56) obtaining complete remission after a median of 4 weeks. Tapering of corticosteroids was possible in both acute (17/23, 73%) and chronic graft-versus-host disease (32/56, 57.1%) groups. Overall survival was 47% (CI: 23-67%) at 6 months for patients with aGVHD (62 vs 28% in responders vs non-responders) and 81% (CI: 63-89%) at 1 year for patients with cGVHD (83 vs 76% in responders vs non-responders). Ruxolitinib in the real life setting is an effective and safe treatment option for GVHD, with an ORR of 69.5% and 57.1% for refractory acute and chronic graft-versus-host disease, respectively, in heavily pretreated patients.
%K Drug development
%K Molecularly targeted therapy
%K Acute Disease
%K Hematopoietic Stem Cell Transplantation
%K Pyrazoles
%~